Bryan Marra
About Bryan Marra
Bryan Marra is a Senior Attorney at Arnold & Porter Kaye Scholer LLP, specializing in pharmaceutical antitrust matters and merger reviews. He has extensive experience in managing e-discovery processes and has represented clients in government investigations across various industries.
Work at Arnold & Porter
Bryan Marra has served as a Senior Attorney at Arnold & Porter Kaye Scholer LLP since 2002. His role involves focusing on antitrust and competition law, particularly in the context of pharmaceutical matters. He engages in merger reviews before federal agencies and is part of the Antitrust/Competition Practice Group. His extensive experience at the firm has allowed him to develop a deep understanding of complex litigation and regulatory compliance.
Education and Expertise
Bryan Marra holds a Bachelor's Degree in Political Science and Economics from the University of Wisconsin-Madison, where he studied from 1994 to 1998. He furthered his education by obtaining a Juris Doctor (J.D.) from Georgetown University Law Center, completing his studies from 1999 to 2002. His educational background provides a strong foundation for his specialized expertise in pharmaceutical antitrust matters, particularly in Hatch-Waxman patent settlements and lifecycle management strategies.
Background
Bryan Marra has significant experience in managing the e-discovery process, which includes leading document production and compliance efforts for high-profile investigations. He has represented clients across various industries, including media, telecommunications, consumer products, and the hospital sector. His background in handling government investigations contributes to his comprehensive understanding of regulatory frameworks and compliance requirements.
Achievements
Throughout his career, Bryan Marra has engaged in complex litigation related to antitrust and competition law. His focus on merger reviews and his representation of clients in diverse industries demonstrate his ability to navigate intricate legal landscapes. His work in pharmaceutical antitrust matters highlights his specialized knowledge in this area, particularly concerning Hatch-Waxman patent settlements.